It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

This forecast represents the total number of people in the United States in 2025 with diabetes, sorted by characteristic. In 2025, some **** million people are expected to have diabetes in the United States.

In 2022, there were almost **** million people who were newly diagnosed with diabetes in the United States. This statistic represents the number of new cases of diagnosed diabetes among U.S. adults per year from 2000 to 2022, in thousands of people.

Diabetes prevalence in Massachusetts has been steadily increasing.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

Around ** percent of the global adult population suffered from diabetes in 2024 - by the year 2050 this number is expected to rise to ** percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke, and is now among the top ten leading causes of death worldwide. Prevalence Diabetes is a global problem affecting many countries. China currently has the largest number of diabetics worldwide, with some *** million people suffering from the disease. However, the highest prevalence of diabetes is found in Pakistan, followed by the Marshall Islands and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease. Outlook It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a *** percent increase in the number of diabetics in the region from 2024 to 2050, while North America and the Caribbean are expected to see an increase of ** percent. In 2050, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth-highest number.

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

The graph displays the number of diabetes-related deaths in the United States from 1999 to 2023. The x-axis represents the years, shown as full four-digit numbers from 1999 to 2023, while the y-axis shows the total number of annual deaths attributed to diabetes. Over this period, the number of deaths ranged from a low of 68,399 in 1999 to a peak of 103,000 in 2021. A sharp rise in diabetes deaths occurred between 2019 and 2021, followed by a gradual decline in the subsequent years. The graph highlights year-to-year changes in diabetes mortality rates.

This dataset contains number and percentage of diabetes patients in the US during 2013 grouped by ZIP code. The prevalence and incidence of diabetes have increased in the United States in recent decades, no studies have systematically examined long-term, national trends in the prevalence and incidence of diagnosed diabetes. The prevalence of diabetes increased substantially between 2000 and 2007, mainly because there are more patients with a new diagnosis each year than those who die. The increase observed by 2007 almost reached the World Health Organization prediction for 2030.

Diabetes Treatment Market Outlook

The global diabetes treatment market size was valued at approximately $50 billion in 2023 and is projected to reach around $90 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5%. This significant growth is primarily driven by the increasing prevalence of diabetes worldwide, advancements in medical technology, and a rising awareness of diabetes management and treatment options.

One of the primary growth factors for the diabetes treatment market is the increasing prevalence of diabetes globally. According to the International Diabetes Federation, the number of people with diabetes is expected to rise from 463 million in 2019 to 700 million by 2045. This alarming increase highlights the urgent need for effective diabetes management and treatment solutions, driving demand in the market. Additionally, lifestyle changes such as urbanization and diet shifts contribute to the rising diabetes rates, further fueling market growth.

Technological advancements in diabetes treatment are another significant growth catalyst. Innovations in insulin delivery systems, continuous glucose monitoring (CGM) devices, and artificial pancreas systems are transforming diabetes care. Improved accuracy, convenience, and patient compliance offered by these technologies enhance diabetes management, thereby boosting market demand. The integration of digital health technologies, such as mobile health apps and telemedicine, also plays a crucial role in supporting diabetes management and monitoring, propelling market growth.

Government initiatives and supportive policies are also driving the growth of the diabetes treatment market. Many governments across the globe are implementing national diabetes programs to improve diabetes care and management. These programs often include funding for research, subsidies for diabetes medications and devices, and public awareness campaigns. Furthermore, collaborations between public and private sectors are fostering innovation and accessibility in diabetes treatment, which is expected to sustain market growth over the forecast period.

From a regional perspective, North America holds a significant share of the diabetes treatment market due to the high prevalence of diabetes, well-established healthcare infrastructure, and strong presence of key market players. Europe follows closely, driven by a growing diabetic population and favorable reimbursement policies. The Asia Pacific region is anticipated to witness the fastest growth, attributed to increasing urbanization, rising healthcare expenditure, and a large undiagnosed diabetic population. Meanwhile, Latin America and the Middle East & Africa regions are expected to experience steady growth owing to improving healthcare access and growing awareness of diabetes management.

Product Type Analysis

In the diabetes treatment market, the product type segment is categorized into Insulin, Oral Hypoglycemic Agents, Non-Insulin Injectable Drugs, and Others. Insulin remains a cornerstone in diabetes management, particularly for individuals with Type 1 diabetes and advanced Type 2 diabetes. The development of various insulin formulations, such as rapid-acting, long-acting, and premixed insulins, caters to the diverse needs of diabetic patients. Additionally, innovations like insulin pens and pumps enhance the convenience and accuracy of insulin administration, supporting the growth of this segment.

Oral Hypoglycemic Agents (OHAs) represent another critical segment in diabetes treatment, particularly for Type 2 diabetes management. OHAs include medications such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors, which help to lower blood glucose levels through different mechanisms. The increasing prevalence of Type 2 diabetes, along with a growing focus on combination therapies to improve glycemic control, is driving the demand for OHAs. Additionally, the development of new classes of oral medications with improved efficacy and safety profiles is expected to further boost this segment.

Non-Insulin Injectable Drugs, including GLP-1 receptor agonists and amylin analogs, offer alternative treatment options for diabetes management. These injectable drugs help to control blood sugar levels and provide additional benefits such as weight loss and cardiovascular protection. The growing preference for non-insulin injectables among patients and healthcare providers is contributing to the expansion of this segment. Moreover, ongoing research and development efforts aimed at enhancing the delivery and efficacy of these

In 2023, West Virginia had the highest share of adults (**** percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

These datasets provide de-identified insurance data for diabetes. The data is provided by three managed care organizations in Allegheny County (Gateway Health Plan, Highmark Health, and UPMC) and represents their insured population for the 2015 and calendar years. Disclaimer: Users should be cautious of using administrative claims data as a measure of disease prevalence and interpreting trends over time, as data provided were collected for purposes other than surveillance. Limitations of these data include but are not limited to: misclassification, duplicate individuals, exclusion of individuals who did not seek care in past two years and those who are: uninsured, enrolled in plans not represented in the dataset, or were not enrolled in one of the represented plans for at least 90 days.

Number and percentage of persons having been diagnosed with diabetes, by age group and sex.

The crude prevalence rate of diabetes is defined as the ratio of respondents that are 18 years or older who have ever been told by a health professional that they had diabetes (other than during pregnancy) over the total number of respondents in the study (excluding those who refused to answer, had a missing answer, or answered “don’t know/not sure”).Prevalence data are derived from Behavioral Risk Factor Surveillance System (BRFSS) (numerator) and population estimates from the U.S. Census Bureau (denominator).The 500 Cities Project seeks to provide city- and census tract-level small area estimates for chronic disease risk factors, health outcomes, and clinical preventive service use for the largest 500 cities in the United States.Data source: CDC (Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion)Date: 2015

This forecast represents the number of people in the United States in 2025 with diagnosed and undiagnosed diabetes, divided by characteristic. In 2025, some **** million people are expected to be diagnosed with diabetes and some **** million people are expected to live with undiagnosed diabetes.

Diabetes Management Platform Market Outlook

The global diabetes management platform market is projected to grow significantly, with a market size valued at approximately $18 billion in 2023 and expected to surge to nearly $35 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 7.5%. This growth is primarily driven by the increasing prevalence of diabetes globally, advancements in healthcare technology, and the growing awareness and need for effective diabetes management solutions. The diabetes management platform market is witnessing profound changes due to technological innovations, increased healthcare expenditure, and the integration of artificial intelligence and machine learning in healthcare platforms, which are enhancing patient outcomes and streamlining diabetes management processes.

A major growth factor in the diabetes management platform market is the increasing prevalence of diabetes worldwide. With lifestyle changes and rising obesity rates, diabetes has become a global health challenge, necessitating advanced management solutions. The International Diabetes Federation estimates that the number of people with diabetes is expected to rise, fueling the demand for effective management platforms. These platforms offer real-time monitoring and data analytics, which are critical in managing the disease effectively. Moreover, increasing health awareness and the push for preventive healthcare have prompted patients and healthcare providers to adopt comprehensive management systems that offer holistic care solutions, further driving market growth.

Technological advancements are another pivotal growth driver for the diabetes management platform market. The integration of digital health technologies, such as telemedicine, artificial intelligence, and mobile health applications, has revolutionized diabetes management, making it more efficient and patient-centric. Companies are investing heavily in research and development to enhance the capabilities of diabetes management platforms, offering features like predictive analytics, personalized treatment plans, and real-time monitoring. These innovations are not only improving patient adherence and outcomes but also enabling healthcare providers to offer more precise and personalized care, thereby accelerating market expansion.

The increasing focus on personalized medicine is also fueling the growth of the diabetes management platform market. Patients are increasingly seeking tailored treatments that cater to their specific needs, propelling the demand for platforms that offer customized solutions. Personalized diabetes management platforms use data analytics and machine learning to analyze patient data and provide individualized treatment plans, enhancing patient engagement and adherence. This shift towards personalized care is not only improving clinical outcomes but also reducing the overall healthcare costs, making diabetes management platforms an attractive solution for both patients and healthcare providers.

Diabetes Management Devices play a crucial role in the evolving landscape of diabetes care. These devices, including glucose meters, insulin pumps, and continuous glucose monitoring systems, are integral to the effective management of diabetes. With technological advancements, these devices have become more accurate, user-friendly, and connected, allowing for seamless integration with digital health platforms. This integration not only enhances the monitoring capabilities but also provides patients and healthcare providers with real-time data, enabling timely interventions and personalized treatment plans. As the demand for efficient and comprehensive diabetes management solutions grows, the development and adoption of advanced diabetes management devices are expected to accelerate, contributing significantly to the overall market expansion.

Regionally, the diabetes management platform market exhibits diverse growth patterns. North America holds a substantial share of the market, driven by a high prevalence of diabetes, advanced healthcare infrastructure, and significant investments in digital health technologies. Europe follows closely, with a focus on innovative healthcare solutions and favorable government initiatives supporting diabetes management. In the Asia Pacific region, the market is witnessing rapid growth due to the increasing diabetic population, rising healthcare expenditure, and growing awareness about diabetes management. Emerging economies in Latin America and the Middle East & Africa are also showing potential for gr

Global Diabetes Care Devices market size was USD 10.26 Billion in 2022 and it is forecasted to reach USD 18.69 Billion by 2030. Diabetes Care Devices Industry's Compound Annual Growth Rate will be 8.76% from 2023 to 2030. Market Dynamics of the Diabetes Care Devices Market

Drivers of the diabetes care device market:

The demand for monitoring and treatment devices is being fuelled by an increase in diabetes prevalence worldwide

Diabetes is becoming more common everywhere, but notably in developing nations like China and India. The prevalence of diabetes is fast increasing, and this is due to a number of causes, including growing urbanisation and an increase in sedentary lifestyle, particularly in developing nations. According to the International Diabetes Federation, there were 425 million adult diabetics worldwide in 2017, and by 2045, that number is expected to reach 630 million. These studies suggest that between 55 and 60 percent of people worldwide have diabetes, with the majority living in China, India, United States, Brazil, and Mexico. Currently, China and India make up about half of the world's diabetic population.

Restraining Factor of the diabetic device care market:

Diabetes care devices tend to be quite expensive and challenging to use

The glucose testing machine is high in price and uncomfortable to use. Diabetes care devices outcomes are not always precise. Additionally, a few things prevent the market from growing. This includes uncomfortable sensor insertions on the body. Additionally, the diabetes care devices cause skin rashes, adhesion problems.

Impact of the COVID-19 pandemic on the Diabetes Care Devices Market: COVID-19 increased the market growth for diabetic care equipment. This is due to the fact that patients with COVID-19 infections were seen to have elevated blood sugar levels. Due to the rising prevalence of diabetes and the expanding market, various firms have introduced innovative, cutting-edge diabetes care devices in the post-pandemic era. One of the biggest global health crises of the twenty-first century is diabetes. This illness, which can cause life-altering problems, is being lived with by an increasing number of people each year. In addition to more than millions adults with impaired glucose tolerance who are at a high risk of getting diabetes in the future, there are an estimated more than half of million adults with diabetes worldwide. With rising obesity rates, shifting food preferences, and an ageing population, diabetes incidence and prevalence are on the rise. Therefore, there is a sizable market potential in the global diabetes care devices & pharmaceuticals market given the enormous numbers of diabetics globally and the enormous financial implications connected with diabetes and linked subsequent health issues.